MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 142 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $43,297,299 | -30.9% | 296,438 | +9.3% | 0.01% | -28.6% |
| Q2 2023 | $62,674,689 | +4.3% | 271,319 | +9.4% | 0.01% | -12.5% |
| Q1 2023 | $60,094,288 | +87414.3% | 248,057 | +4.8% | 0.01% | -20.0% |
| Q4 2022 | $68,668 | -99.5% | 236,585 | +3.0% | 0.01% | +400.0% |
| Q3 2022 | $14,933,000 | -7.2% | 229,786 | +2.2% | 0.00% | 0.0% |
| Q2 2022 | $16,091,000 | -24.8% | 224,802 | +3.1% | 0.00% | -33.3% |
| Q1 2022 | $21,388,000 | +14.7% | 217,988 | -0.9% | 0.00% | +50.0% |
| Q4 2021 | $18,644,000 | +15.5% | 220,018 | +8.7% | 0.00% | 0.0% |
| Q3 2021 | $16,147,000 | -16.3% | 202,375 | +2.2% | 0.00% | -33.3% |
| Q2 2021 | $19,297,000 | +6.6% | 198,104 | +28.0% | 0.00% | 0.0% |
| Q1 2021 | $18,106,000 | +14.7% | 154,796 | +9.0% | 0.00% | 0.0% |
| Q4 2020 | $15,786,000 | -3.7% | 142,006 | +2.9% | 0.00% | 0.0% |
| Q3 2020 | $16,387,000 | +4.3% | 138,026 | -0.6% | 0.00% | 0.0% |
| Q2 2020 | $15,717,000 | +69.5% | 138,790 | -0.1% | 0.00% | +50.0% |
| Q1 2020 | $9,274,000 | -58.9% | 138,920 | -44.0% | 0.00% | 0.0% |
| Q4 2019 | $22,582,000 | +134.1% | 247,866 | +121.5% | 0.00% | 0.0% |
| Q3 2019 | $9,648,000 | -15.9% | 111,901 | +2.2% | 0.00% | -33.3% |
| Q2 2019 | $11,473,000 | -8.0% | 109,468 | +9.9% | 0.00% | 0.0% |
| Q1 2019 | $12,472,000 | -38.9% | 99,573 | -45.0% | 0.00% | 0.0% |
| Q4 2018 | $20,404,000 | +10.8% | 181,032 | +110.6% | 0.00% | -40.0% |
| Q3 2018 | $18,410,000 | -17.7% | 85,980 | +7.5% | 0.01% | -28.6% |
| Q2 2018 | $22,379,000 | +272.1% | 80,016 | +55.4% | 0.01% | +250.0% |
| Q1 2018 | $6,014,000 | +20.7% | 51,502 | -5.2% | 0.00% | 0.0% |
| Q4 2017 | $4,984,000 | +208.0% | 54,299 | +50.9% | 0.00% | +100.0% |
| Q3 2017 | $1,618,000 | +208.8% | 35,980 | +11.6% | 0.00% | – |
| Q2 2017 | $524,000 | +32.0% | 32,240 | +24.9% | 0.00% | – |
| Q1 2017 | $397,000 | +4.2% | 25,821 | +0.8% | 0.00% | – |
| Q4 2016 | $381,000 | +64.2% | 25,605 | +39.8% | 0.00% | – |
| Q3 2016 | $232,000 | – | 18,317 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |